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Abstract
Nontuberculous mycobacteria (NTM) are a large group of environmental organisms with
worldwide distribution, but only a relatively few are known to be pathogenic. Chronic, debili-
tating lung disease is the most common manifestation of NTM infection, which is often re-
fractory to treatment. The incidence and prevalence of NTM lung disease are increasing in
the United States and in many parts of the world. Hence, a more complete understanding of
NTM pathogenesis will provide the foundation to develop innovative approaches to treat
this recalcitrant disease. Herein, we demonstrate that several species of NTM show broad
resistance to the antimicrobial peptide, cathelicidin (LL-37). Resistance to LL-37 was not
significantly different betweenM. avium that contain serovar-specific glycopeptidolipid
(GPL,M. aviumssGPL) andM. avium that do not (M. aviumΔssGPL). Similarly,M. abscessus
containing non-specific GPL (M. abscessusnsGPL(+)) or lacking nsGPL (M. abscessusnsGPL
(-)) remained equally resistant to LL-37. These findings would support the notion that GPL
are not the components responsible for NTM resistance to LL-37. Unexpectedly, the growth
ofM. abscessusnsGPL(-) increased with LL-37 or scrambled LL-37 peptide in a dose-depen-
dent fashion. We also discovered that LL-37 exposed to NTM had reduced antimicrobial
activity, and initial work indicates that this is likely due to inactivation of LL-37 by lipid com-
ponent(s) of the NTM cell envelope. We conclude that pathogenic NTM resist and inactivate
LL-37. The mechanism by which NTM circumvent the antimicrobial activity of LL-37 remains
to be determined.
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Introduction
Nontuberculous mycobacteria (NTM) are aquaphilic and geophilic environmental organisms
frequently recovered from potable and natural water sources, plumbing systems, and soil
[1–3]. The majority of the more than 169 catalogued NTM species are not known to be
pathogenic, but several, includingMycobacterium avium,Mycobacterium intracellulare,My-
cobacterium abscessus,Mycobacterium kansasii,Mycobacterium xenopi, andMycobacterium
malmoense are clinically significant and of growing concern for several reasons [4]. First, the
incidence and prevalence of NTM lung disease are on the rise [5–9]. Second, NTM pulmonary
infections are expensive to treat, ranking second only to Legionnaires’ disease for inpatient
treatment costs attributed to water-associated diseases [10]. Third, while the prevailing notion
is that NTM are not contagious [11, 12], person-to-person transmission has been proposed
[13]. Fourth, NTM lung diseases are often resistant to treatment despite the use of lengthy,
multi-drug regimens [14].
The surface of most bacteria including the cell wall of NTM is negatively charged, allowing
cationic antimicrobial peptides to bind and serve as first line, innate immune defenses against
invading pathogens [15, 16]. The antimicrobial peptide cathelicidin (LL-37), binds, inserts, and
forms pores in the negatively charged membrane of a variety of Gram-negative and Gram-pos-
itive bacteria [17–20]. LL-37 has also been shown to killMycobacterium tuberculosis (Mtb) [18,
21]. Despite its broad-spectrum of activity, LL-37 did not inhibit the growth ofM. avium homi-
nissuis [22, 23].
In the current study, we sought to examine whether other clinically relevant pathogenic spe-
cies of NTM includingM. avium Chester andM. intracellulare are resistant to LL-37. Since
NTM cell envelope components have been implicated to play a role in immune evasion, they
may also contribute to resistance against LL-37 [22]. Among the various cell wall components
of NTM that have been characterized, glycopeptidolipids (GPL) are lipid molecules linked to
the pathogenesis of NTM infections [24–30]. More specifically, GPL are unique to NTM and
contribute to colony morphology, sliding motility, and biofilm formation [31–35]. NTM such
asM. avium produce polar serovar-specific GPL (ssGPL) comprised of unique serovar-specific
oligosaccharides covalently bound to a basic tripeptide amino acid alcohol core, fatty acid,
methylated rhammose, and 6-deoxytalose [36–38]. Other NTM such asM. abscessus do not
produce ssGPL, but rather express non-polar, diglycosylated non-specific GPL (nsGPL) [32].
Thus, we also investigated whether resistance to LL-37 inM. avium andM. abscessus strains is
dependent on GPL. Finally, we determined whether the antimicrobial activity of LL-37 is com-
promised after incubation with NTM.
Materials and Methods
Bacteria
Salmonella enteriditis Uganda and Salmonella non-typhi Nairobi were kind gifts from Dr. Ed-
ward Janoff (University of Colorado Anschutz Medical Campus, Aurora, Colorado).M. avium
Chester was obtained from ATCC (#700737) andM. intracellulare 9141 was kindly provided
by Dr. Leonid Heifits (National Jewish Health) [39].
The original characterization ofM. avium 920A6 serovar 8 wildtype and the allelic ex-
change mutagenesis of the rhamnosyltransferase (rtfA) gene to generate a null strain lacking
ssGPL have been previously reported [40]. In this study, we refer toM. avium serovar 8 wild-
type asM. aviumssGPL (containing ssGPL) and the ssGPL null strain asM. aviumΔssGPL (lack-
ing ssGPL).
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M. abscessus produce only nsGPL [32].M. abscessus variants with nsGPL (M. abscessusnsGPL(+))
on the cell surface are referred to as the smooth morphotype whereas those lacking nsGPL (M.
abscessusnsGPL(-)) are known as rough morphotype.M. abscessus smooth was obtained from
ATCC (#19977) andM. abscessus rough was a clinical isolate cultured from a patient with cystic
fibrosis (CF31) (Dr. Lindsay Caverly, National Jewish Health, Denver, Colorado).
Bacterial cultures
Laboratory strains of Escherichia coli and Salmonella species were cultured in Luria Bertani
(LB) broth to obtain stock cultures. All NTM strains were cultured in 7H9 broth with ADC en-
richment supplement to obtain stock cultures.MtbH37Rv was handled under BSL3 safety con-
ditions as previously described [41].
Synthetic bioactive LL-37
The synthetic human LL-37 peptide (NH2-LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR
TES-COOH) and scrambled LL-37 (NH2—GLKLRFEFSKIKGEFLKTPEVRFRDIKLKDN
RISVQR—COOH) were synthesized by the Peptide Core, University of Colorado Anschutz
Medical Campus. The peptides were purified by preparative reverse-phase high performance
liquid chromatography (HPLC), verified by analytical reversed-phase HPLC, and molecular
mass determined by electrospray mass spectrometry. Purity for both LL-37 and scrambled LL-
37 peptide was>98%. The lyophilized peptides were stored at -20C and resuspended in 0.1%
trifluoroacetic acid (final pH 2.0) before use.
Antibacterial assays and bacterial detection
The antibacterial assay culture medium for LL-37 was previously optimized (RPMI-1640 sup-
plemented with sodium bicarbonate pH 7.3; diluted 1:4 in distilled water) [21] and referred
henceforth as the “LL-37 medium.” In each kill assay, 2x105 to 2x106 bacteria per 250 μl LL-37
medium (pH 7.0) were incubated with various concentrations of LL-37. The tubes were vigor-
ously vortexed, rotated, and incubated at 37°C up to 96 hours. Killing efficacy was analyzed by
performing serial dilutions of bacterial-peptide cocktail. Each dilution was plated in duplicate
onto agar plates that were incubated at 37°C. E. coli and Salmonella species were inoculated on
LB plates and incubated overnight, while rapidly-growing (M. abscessus) and slow-growing
mycobacteria (M. avium and M. intracellulare) were incubated for 3–5 days or 10–14 days, re-
spectively on 7H10 agar plates. Colony forming units (CFU) were manually scored. A mini-
mum of three or more independent experiments were completed for all antibacterial assays.
GPL isolation and thin layer chromatography
The presence of GPL fromM. aviumssGPL and the absence of GPL from theM. aviumΔssGPL
mutant were previously confirmed by thin layer chromatography (TLC) [40].M. absces-
susnsGPL(+) andM. abscessusnsGPL(-) variants were grown in separate 25 ml 7H9 broth cultures
and GPL extracted using previously described methods [42, 43]. Lipids were saponified by in-
cubation at 37°C for 20 minutes in 0.2M NaOH/methanol and neutralized with glacial acetic
acid (0.1M final concentration). The samples were centrifuged at 20,000 x g for 10 minutes,
evaporated using N2, and resuspended in chloroform:methanol (2:1). A portion of the clarified
organic phase was spotted onto silica plates for analysis by TLC using a chloroform:methanol:
H2O (100:14:0.8) solvent system. Each plate was dipped in 0.1% orcinol/5%H2SO4 and placed
under dry heat (100°C for 20 minutes) for visualization of lipids.
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Fraction purification fromM. abscessus andM. intracellulare
Total lipid fractions were extracted from cell pastes ofM. abscessusnsGPL(+) andM. intracellu-
lare (11.4 g and 9.5 g, respectively). Briefly, pulses from a microfluidizer, intermittent cycles of
sonication, and three to four cycles of bead beating (Zironia/Silica beads 11079101z BioSpec)
were used to lyse the bacteria. Beads and insoluble debris were removed by centrifugation for
five minutes at 3000 x g at 4°C. A portion of the resultant whole cell lysate (WCL) was reserved,
with the remaining WCL further separated to generate cell wall (CW), cell membrane (CM),
and cytosol fractions by established methods [44, 45]. Lipids of each subcellular fraction were
obtained by sequential extraction with chloroform:methanol (2:1) as described previously [45].
Finally, the insoluble cell wall (ICW) fraction was obtained by exhaustive extraction of delipi-
dated CW with SDS to remove proteins followed by harvest of ICW via centrifugation [46].
Each fraction was aliquoted into pre-weighed vials, lyophilized under N2 air, and re-weighed to
determine component mass.
E. coli bioassays as a readout for LL-37 antimicrobial activity
To test whether LL-37 exposed to NTM- or NTM-derived fractions is inactivated, E. coli
growth was monitored by two different bioassays. In the first bioassay, NTM cultures incubat-
ed with LL-37 for 96 hours were centrifuged at 6,000 x g, which pellets the bacteria, and leaves
any residual LL-37 in the supernatant. Next, the culture supernatant was transferred into new
microfuge tubes to which 2x105 E. coli was inoculated and incubated for four hours. After incu-
bation, serial dilutions were performed and inoculated onto duplicate LB agar plates, incubated
for four hours, and E. coli CFU enumerated. In the second bioassay, 10 μg of each NTM-de-
rived lipid fraction was resuspended in DMSO to which 250 μl of LL-37 medium was added.
The final concentration of DMSO in each sample was<0.1%. Next, 25μg/ml of fresh LL-37
was added to each NTM fraction and pre-incubated at 37°C for four hours. Subsequently,
2x105 E. coli was inoculated into each of the samples, incubated for an additional 16 hours, and
swabbed onto LB agar plates to assess bacterial growth.
Statistical analyses
The data were analyzed with GraphPad using paired t-tests or two-way ANOVA to determine
statistical significance. Values with p<0.05 were considered statistically significant. Data are
expressed as means ± S.E.M. for three or more independent determinations for each experi-
mental point.
Results
Synthetic LL-37 possesses broad-spectrum antibacterial activity
To validate the antibacterial activity of the synthesized LL-37, LL-37 at concentrations of
0–25 μg/mL was added to E. coli cultures and CFU quantified. Incubation with 25 μg/ml LL-37
effectively killed E. coli after four hours (Fig 1A and 1B), consistent with previous reports [47,
48]. LL-37 at 1–50 μg/ml also demonstrated antimicrobial activity against various species of
Salmonella including a non-pathogenic laboratory isolate (Fig 2A) and two pathogenic clinical
isolates (Fig 2B and 2C). Similar to a previous report [21], ten μg/ml of LL-37 incubated with
Mtb reduced viability, but the reduction was not statistically significant (Fig 2D). Overall, syn-
thetic LL-37 has antimicrobial activity against a variety of bacteria.
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M. avium Chester andM. intracellulare are resistant to LL-37
To evaluate the effectiveness of LL-37 against NTM species,M. avium Chester andM. intracel-
lulare were separately incubated with 10, 125, 250, and 500 μg/ml LL-37 for up to 96 hours and
CFU determined. In contrast to the aforementioned findings, there was no significant change
in the viability ofM. avium Chester orM. intracellulare at all LL-37 concentrations and time
points tested (Fig 3A and 3B). We also found no significant change in viability of 48-hour log
phase cultures incubated with up to 250 μg/ml of LL-37 (data not shown).
M. aviumssGPL andM. aviumΔssGPL serovar 8 are equally resistant to
LL-37
To investigate whether ssGPL contribute to the resistance ofM. avium to LL-37,M. aviumssGPL
serovar 8 andM. aviumΔssGPL were incubated with increasing concentrations of LL-37 and
CFU quantified at various times. As shown in Fig 4, bothM. aviumssGPL andM. aviumΔssGPL
were resistant to LL-37 at all concentrations and time points examined. In contrast, gentamicin
significantly reduced the growth of both variants after 48 and 96 hours.
Fig 1. E. coli is susceptible to LL-37. (A) Log10 CFU of E. coli after 4 hours of incubation with 0, 10, or 25 μg/
ml of LL-37. **p< 0.001; ***p<0.0001. Data are the mean ± SEM of 6 independent experiments. (B) Images
were taken of each serial dilution on LB agar from E. coli cultures incubated for 4 hours in the absence or
presence of 25 μg/ml of LL-37.
doi:10.1371/journal.pone.0126994.g001
Fig 2. LL-37 demonstrates broad-spectrum antimicrobial activity. Log10 CFU after 1–8 hours of
incubation of a (A) laboratory isolate of Salmonella enteriditis or clinical isolates of (B) Salmonella enteriditis
(Uganda) or (C) Salmonella non-typhi (Nairobi) with 0–50 μg/ml of LL-37. *p< 0.01; **p< 0.001;
***p<0.0001. Data are the mean ± SEM of 3–6 independent experiments. (D)Mtb H37Rv were incubated
with 10 μg/ml LL-37 and the percent change in CFU calculated after 96 hours incubation. n = 3
independent experiments.
doi:10.1371/journal.pone.0126994.g002
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BothM. abscessusnsGPL(+) and nsGPL(-) variants are equally resistant to
LL-37
We also incubated a strain ofM. abscessus that contains nsGPL (M. abscessusnsGPL(+)) with var-
ious concentrations of LL-37 for up to 96 hours. We found thatM. abscessusnsGPL(+) was
completely resistant to LL-37 at all concentrations and time points tested (Fig 5A). To deter-
mine whether the nsGPL present on the wildtypeM. abscessus is responsible for this resistance,
the growth of aM. abscessus variant devoid of nsGPL (M. abscessusnsGPL(-)) was tested against
LL-37. After 48 and 96 hours of incubation in the absence of LL-37, the growth ofM. absces-
susnsGPL(-) was significantly slower thanM. abscessusnsGPL(+) (Fig 5B compared to 5A, black
bars). In the presence of LL-37, neitherM. abscessus strain was killed by LL-37. On the con-
trary,M. abscessusnsGPL(-) was not only resistant to LL-37, but unexpectedly showed significant
increases in growth when incubated with increasing concentrations of LL-37 compared to the
untreated cultures (Fig 5B). Thin layer chromatography confirmed the presence and absence of
GPL inM. abscessusnsGPL(+) andM. abscessusnsGPL(-), respectively (Fig 5C).
To examine whether the enhanced growth of theM. abscessusnsGPL(-) cultured with LL-37
was dependent on the primary structure of LL-37,M. abscessusnsGPL(-) andM. abscessusnsGPL(+)
strains were incubated for 24, 48, and 96 hours with varying concentrations of an LL-37 peptide
in which the amino acid sequence are randomly scrambled and CFU determined. Similar to that
Fig 3. PathogenicM. avium andM. intracellulare are resistant to LL-37.Growth curves of (A)M. avium
Chester (p = 0.28) and (B)M. intracellulare (p = 0.89) after incubation with 0, 10, 125, 250, or 500 μg/ml of LL-
37. Data are the mean ± SEM of 3–6 independent experiments.
doi:10.1371/journal.pone.0126994.g003
Fig 4. ssGPL does not contribute to the resistance ofM. avium to LL-37.CFU determination ofM.
aviumssGPL andM. aviumΔssGPL serovar 8 after incubation with 0, 10, 25, and 100 μg/ml LL-37 and 20 μg/ml
gentamicin. ***p<0.0001. Data are the mean ± SEM of 3 independent experiments.
doi:10.1371/journal.pone.0126994.g004
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seen following incubation with LL-37,M. abscessusnsGPL(+) viability was not affected by scram-
bled LL-37 at any concentration or time point tested (Fig 5D) whereasM. abscessusnsGPL(-)
growth also increased after incubation with scrambled LL-37 (Fig 5E).
LL-37 exposed to NTM or NTM-derived fractions loses antibacterial
activity
Since we did not observe killing of NTM by LL-37, we investigated the possibility that NTM-
exposed LL-37 may have become inactivated. In a bioassay, E. coli was added to culture super-
natants ofM. intracellulare,M. avium Chester,M. abscessus, andMtb originally incubated with
500 μg/ml LL-37 for 96 hours. E. coli cultured in medium alone showed viable cells, which
were killed in the presence of LL-37 (Fig 6A). However, when E. coli was incubated with LL-
37-containing NTM culture supernatants, no significant decrease in viable E. coli was observed
(Fig 6A); in contrast, no viable E. coli was recovered after incubation with LL-37-containing
Mtb culture supernatant (Fig 6A).
To determine if the NTM component(s) that inactivates LL-37 is heat labile, culture super-
natants fromM. intracellulare,M. avium Chester, andM. abscessus incubated for 96-hours
without the addition of LL-37 were boiled and cooled to room temperature prior to the addi-
tion of E. coli and fresh LL-37 peptide. These bioassays demonstrated that E. coli remained via-
ble and replicated well despite incubation with LL-37 in the presence of boiled NTM culture
supernatant (Fig 6B).
Based on our findings thus far, it appears that a secreted, or surface exposed, heat-stable
component of the NTM cell envelope inactivates LL-37. To begin to dissect which component
(s) of NTM inactivates LL-37, large-scale preparations ofM. abscessus andM. intracellulare
were prepared and chloroform:methanol was used to separate the total lipids of the CM and
CW fractions from the glycans and proteins. Fresh LL-37 (25 μg/ml) and E. coli were added to
the total lipid fractions of the CM/CW or the ICW fraction per unit of dry weight to test the
ability of each fraction to inactivate LL-37. E. coli was killed when incubated with LL-37 alone
Fig 5. nsGPL do not mediate the resistance ofM. abscessus to LL-37. (A-B) CFU determination ofM.
abscessusnsGPL(+) in the presence of the indicated concentrations of native LL-37 (p = 0.69). Data are the
mean ± SEM of 4 independent experiments. (B) CFU determination ofM. abscessusnsGPL(-) in the presence
of the indicated concentrations of native LL-37. Data are the mean ± SEM of 4 independent experiments.
*p<0.01; **p< 0.001; ***p<0.0001. (C) Thin-layer chromatography demonstrates the presence and
absence of GPL inM. abscessusnsGPL(+) andM. abscessusnsGPL(-), respectively. (D-E) CFU determination of
M. abscessusnsGPL(+) andM. abscessusnsGPL(-), respectively in the presence of the indicated concentrations
of scrambled LL-37 peptide. Data are the mean ± SEM of 3 independent experiments. *p<0.01; **p< 0.001;
***p<0.0001.
doi:10.1371/journal.pone.0126994.g005
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and LL-37 with ICW; however, viable E. coli was recovered after incubation with LL-37 plus ei-
therM. abscessus orM. intracellulare CM or CW total lipid fractions (Fig 6C). As a control, E.
coli was incubated with just the buffer solutions used to resuspend each of theM. abscessus and
M. intracellulare fractions (vehicle control); in all cases, E. coli replicated in the absence of LL-
37, but were killed in the presence of LL-37 in these NTM-naïve solutions (data not shown).
Discussion
We discovered that LL-37, despite being highly active against E. coli, various Salmonella spe-
cies, andMtb H37Rv, was inactive against four NTM species tested.M. avium andM. abscessus
strains with genetic disruption for their respective GPLs (M. aviumΔssGPL andM. absces-
susnsGPL(-)) remained resistant to LL-37. Thus, GPL is unlikely to be the NTM component that
mediates resistance to LL-37. Indeed, the growth ofM. abscessusnsGPL(-) unexpectedly and con-
sistently increased when incubated with either native LL-37 or scrambled peptide. Our data
also indicate that LL-37 exposed to either NTM or NTM-derived CM or CW total lipid frac-
tions becomes inactivated. Taken together, our findings indicate that NTM are resistant to LL-
37, inactivate the antimicrobial activity of LL-37, and that the NTM-derived component(s)
that inactivate LL-37 are likely to be polar lipids or similarly hydrophilic component(s) of the
NTM cell envelope that is extractable with an organic solvent.
The finding that many species of NTM are resistant to LL-37 is consistent with a recent re-
port demonstrating resistance ofM. avium hominissuis to LL-37 [22]. Although LL-37 was the
only antimicrobial peptide tested in our studies, resistance to antimicrobial peptides may be a
global defense mechanism of NTM. The differential activity of LL-37 against NTM andMtb is
interesting, but not surprising considering they contain different cell wall components; e.g.,
compared to lipoarabinomannan of NTM, the mannose-capped lipoarabinomannan ofMtb is
Fig 6. Loss of LL-37 activity after exposure to NTM or NTM-derived lipids. E. coli bioassayswere used to
evaluate LL-37 activity. (A) LL-37 remaining in NTM (but notMtb) culture supernatant no longer kills E. coli.
(B) E. coli survives in untreated or boiled NTM culture supernatants to which fresh LL-37 was added. (C) E.
coli survival following incubation withM. abscessus orM. intracellulare derived cell fractions. CM = cell
membrane, CW = cell wall, ICW = insoluble cell wall fraction.
doi:10.1371/journal.pone.0126994.g006
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distinct in structure and elicits a different host-immune response [49]. Moreover, it is well es-
tablished that the surface-exposed lipids of the different mycobacterial species are highly varied
in composition, location, and arrangement which may impact susceptibility or resistance to an-
timicrobial peptides [24].Mtb is a strict intracellular organism and does not survive for extend-
ed periods outside of the host. Compared toMtb, the cell envelope of NTM is likely to be
considerably more impermeable to enhance survival in environments that vary greatly; e.g.,
natural and made-made water systems, soil, and biofilms that can vary with extremes of tem-
perature, humidity, and nutrients [50]. A global comparative lipidomics approach, using re-
cently established methods and mycobacterial lipid databases [51–53] will be required to
identify lipids unique to NTM that possesses this activity.
Although our findings would suggest that GPLs—whether ssGPL inM. avium or nsGPL in
M. abscessus—do not inactivate LL-37, there are at least 31 other serovar-specificM. avium
GPL not examined in this study [36]. But based on the available evidence, it is reasonable to
suspect NTM GPL do not mediate resistance to LL-37. In future studies, it would be informa-
tive to determine whether purified ssGPL from the differentM. avium species includingM.
avium hominissuis, modulate the structure of LL-37.
The finding that the growth of theM. abscessusnsGPL(-) variant increased with increasing
concentrations of LL-37 (or scrambled LL-37) was unexpected. One interpretation of these
findings is that the experimental conditions alone were unfavorable for theM. abscessusnsGPL(-)
variant, but adding increasing concentrations of LL-37 may have sufficiently supplemented
the conditions to facilitate growth. The exact mechanisms to explain this observation are un-
known, but may be due to increased activity of uptake transporters or permeases that internal-
ize and metabolize LL-37 [54, 55]. We recognize an important limitation to these studies is that
theM. abscessusnsGPL(-) andM. abscessusnsGPL(+) variants were not derived from the same pa-
rentalM. abscessus strain; thus, we cannot exclude the possibility that the observed increase in
the growth of theM. abscessusnsGPL(-) variant is due to attributes unique to this particular vari-
ant which may be independent of the absence of nsGPL. IsogenicM. abscessusnsGPL(-) andM.
abscessusnsGPL(+) variants should be used in future studies to confirm these findings.
Bacterial evasion of host-protective LL-37 is common. In fact, there are a wide variety of
evasion strategies employed by numerous bacterial species to avoid LL-37 including modifica-
tion of normally anionic cell surface constituents with cationic molecules to repel LL-37,
antimicrobial peptide trapping mechanisms, secretion of proteases that cleave LL-37, and
downregulation of antimicrobial peptide transcription (reviewed in [50]). Our findings indi-
cate that components of the NTM cell envelope contribute to LL-37 resistance, and, more spe-
cifically, heat-stable CM and/or CW lipids exert the anti-LL-37 activity.
In summary, the finding that clinically relevant species of NTM are uniquely resistant to
and neutralize LL-37 provides a pathogenic mechanism for why it is difficult to eradicate these
organisms once the infection becomes established. Elucidating the mechanism by which
NTM resist and inactivate LL-37 will provide leverage in developing more unconventional ap-
proaches to therapeutics with novel mechanisms of action to slow the progression of this
emerging lung disease; i.e., development of agents to counter the NTM component(s) that neu-
tralize LL-37.
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